Gut

Journal of the British Society of Gastroenterology which is a registered charity

than 7%,[3,4] at the time of diagnosis. The authors note, however, that two patients within the Northern Region Register presented with right sided colonic polyps but no evidence of rectal polyps. Despite this finding, they still advocate rigid or flexible proctosigmoidoscopy as an adequate screening procedure of 'at risk' family members.

We feel it should be emphasised that within this high risk population, a large subset of patients present with 'rectal sparing' at initial diagnosis. As many as 20% of patients with familial adenomatous polyposis present with numerous colonic polyps in the total absence of rectal polyps.[5] Furthermore, invasive colonic carcinoma has been noted in up to 8% of this group, with no evidence of rectal polyposis.[5] This was recently reinforced to ourselves, when a young man presented with invasive colonic carcinoma and extracolonic manifestations of the syndrome, but no macroscopic evidence of polyps on rigid proctosigmoidoscopy. As illustrated in our own experience, we believe that rigid proctosigmoidoscopy is too limited an investigation to adequately screen the colorectal mucosa of these at risk family members, as rigid proctosigmoidoscopy alone has a potential false negative diagnostic rate as high as 20%, which may delay prophylactic colectomy and allow progression to colonic malignancy in screened subjects.

We suggest that first degree relatives identified as carriers of the abnormal familial adenomatous polyposis gene (as detected by haematological screening for linked genetic DNA markers), should be screened every 12 months by flexible sigmoidoscopy as a minimum, and colonoscopy as the ideal; and every 3 years in family members with negative linkage markers. The role of rigid sigmoidoscopy should be confined to regular long term follow up of patients at risk of rectal carcinoma following subtotal colectomy and ileorectal anastomosis.

Screening 'at risk' family members with flexible sigmoidoscopy or colonoscopy will minimise delays in diagnosis of affected subjects, and therefore reduce the incidence of colonic carcinoma within the screened population.

I S TAIT
D J BYRNE
J C FORRESTER
Department of Surgery,
Ninewells Hospital and Medical School,
Dundee DD1 9SY

1 Bulow S. Familial adenomatous polyposis. *Ann Med* 1989; **21**: 299–307.
2 Bulow S. Diagnosis of familial adenomatous polyposis. *World J Surg* 1991; **15**: 41–6.
3 Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. *Gut* 1992; **33**: 357–60.
4 Macrae FA, St John DJ, Muir EP, Penfold JC, Cuthbertson AM. Impact of a hospital-based register on the management of familial adenomatous polyposis. *Med J Aust* 1989; **151**: 552–7.
5 Bess MA, Martin AD, Elveback LR, Moertel CG. Rectal cancer following colectomy for polyposis. *Arch Surg* 1980; **115**: 460–6.

Reply

EDITOR,—We thank Tate *et al* for highlighting the problems of routine screening in familial adenomatous polyposis. We appreciate that there is a definite incidence of rectal sparing in familial adenomatous polyposis although the current experience in the Northern Region Register is not as high as the 20% quoted by Bess *et al*.[1] The two patients with rectal sparing in the Northern Region Register referred to by the authors have now been fully reported.[2]

We nevertheless feel that flexible or rigid proctosigmoidoscopy is an adequate screening procedure for most at risk family members and do not consider colonscopy necessary for all 'at risk' individuals. This more invasive investigation should be reserved for selected patient groups. Those patients who have congenital hypertrophy of the retinal pigment epitheliums and unfavourable DNA markers but have not developed polyps by the late teens or early twenties should have proximal polyposis or carcinoma excluded by colonoscopy. Similarly the small group of patients with established but mild polyposis in whom it is considered desirable to delay colectomy must have colonoscopic surveillance. We feel that this selective usage will minimise the number of patients receiving an investigation, which has a definite associated risk of morbidity and death, at no detriment to their care.

D M BRADBURN
M RHODES
Department of Surgery,
The Medical School,
Framlington Place,
Newcastle upon Tyne NE2 4HH

1 Bess MA, Martin AD, Elveback LR, Moertel CG. Rectal cancer following colectomy for polyposis. *Arch Surg* 1980; 115: 460–6.
2 Bradburn DM, Gunn A, Hastings A, Shepherd NA, Chapman PD, Burn J. Histological detection of microadenomas in familial adenomatous polyposis. *Br J Surg* 1991; **78**: 1394–5.

Bleeding varices in the elderly

EDITOR,—I read with interest the leading article by Triger (*Gut* 1992; **33**: 1009–10) on the management of bleeding oesophageal varices in the elderly. I was surprised that he did not mention transjugular intrahepatic portosystemic shunting (TIPS), a new, minimally invasive interventional radiological technique for the treatment of bleeding varices. A tract is created between the hepatic vein and portal vein and patency is maintained by placement of an expandable metallic stent. The procedure is performed through a 10 French (3·3 mm diameter) sheath sited in the internal jugular vein. Early results using this procedure have been very encouraging.

Unlike surgical portosystemic shunting, TIPS has low procedure related morbidity and mortality. Five patients of the first 59 reported have died in the first thirty days following the procedure; three had Child's Stage C disease and two had sepsis unrelated to the TIPS procedure.[1-5] The oldest patient to undergo a successful TIPS procedure was 78 years old.[2] Encephalopathy following TIPS has been reported in one patient.[3] A recent editorial in the *Lancet* advocates a controlled trial of TIPS *v* injection sclerotherapy for the treatment of bleeding oesophageal varices.[6] All gastroenterologists should be aware of this procedure.

V McDERMOTT
Department of Diagnostic Radiology,
Hospital of the University of Pennsylvania,
3400 Spruce St, Philadelphia, PA 19103,
USA

1 Zemel G, Katzen BT, Becker GJ, Benenati J, Sallee DS. Percutaneous transjugular portosystemic shunt. *JAMA* 1991; **266**: 390–3.
2 Richter GM, Noeldge G, Roessle M, Roeren TH, Kauffman GW, Palmaz JC. Three year results of use of transjugular intrahepatic portosystemic stent shunt. RSNA Abstracts. *Radiology* 1991; **181** (suppl): 99.
3 Roessle M, Noeldge G, Pararnau JM, Haag K, Sellinger M, Wenz W, *et al*. Transjugular intrahepatic portosystemic stent shunt (TIPSS): experience with an improved technique. AASLD Abstracts of Papers. *Hepatology* 1991; **14**: 96A.
4 Ring EJ, Lake JR, Roberts JP, Gordon RL, LaBerge JM, Read AE, *et al*. Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. *Ann Intern Med* 1992; **116**: 304–9.
5 Chalmers N, Redhead DN, Simpson KJ, Hayes PC. Transjugular intrahepatic portosystemic stent shunt (TIPSS): early clinical experience. *Clin Rad* 1992; **46**: 166–9.
6 Anonymous. Bleeding oesophageal varices: IST, EVL, or TIPS. [Editorial]. *Lancet* 1992; **340**: 515–6.

Reply

EDITOR,—I am grateful to Dr McDermott for drawing attention to my omission of transjugular portosystemic shunting (TIPS) in my editorial. While this technique offers exciting prospects for a new therapeutic approach to variceal haemorrhage, I would urge some caution against its uncritical adoption. Reports to date have been based on relatively limited experience from the few specialist centres and, as McDermott points out, no controlled trials have yet been undertaken to compare it with endoscopic sclerotherapy. It is somewhat naive to describe the technique as being 'minimally invasive'; the procedure frequently takes as long as three hours to perform, and there have been several reports of fatal haemoperitoneum because of traumatic rupture of the portal vein/liver.

Anecdotal reports of TIPS being successfully used in elderly patients should not be taken as evidence that the procedure should be readily adopted as an alternative treatment without careful evaluation. Whereas the elderly should not be denied any form of treatment simply on account of their age, it is equally important to ensure that new therapeutic manoeuvres are adequately assessed before being applied to them.

D R TRIGER
University of Sheffield Medical School,
Beech Hill Road,
Sheffield S10 2RX

NOTES

Liver Disease

The XVIIIth International Update on Liver Disease will be held at the Royal Free Hospital School of Medicine, London from 8–10 July 1993. Further information from Professor Neil McIntyre, University Department of Medicine, Royal Free Hospital, Pond Street, London NW3 2QG. (Tel: 071 794 0500 extn 3969; fax: 071 435 5803.)

Gastrointestinal Motility

The 14th International Symposium on Gastrointestinal Motility will be held on 29 August to 3 September 1993 at Minett, Muskoka, Ontario, Canada. Further information from Dr N E Diamant, Chairman, c/o Mrs Diana Valdez, Symposium Co-ordinator, Toronto Hospital (Western Division), 12–419 McLaughlin Pavilion, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8. Tel: 416 369 5075; fax: 416 369 6204.

Gut

Journal of the British Society of Gastroenterology
which is a registered charity

Gut publishes original papers, leading articles, and reviews concerned with all aspects of the scientific basis of diseases of the alimentary tract, liver, and pancreas. Case reports will only be accepted if of exceptional merit. Letters related to articles published in *Gut* or with topics of general professional interest are welcomed. Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

COMMUNICATIONS Two copies of the manuscript and figures should be addressed to the Editor, *Gut*, BMA House, Tavistock Square, London WC1H 9JR, UK. Manuscripts should follow the Vancouver conventions (see *BMJ* 1979; i: 532–5. *Gut* 1979; **20**: 651–2). They should be in double-spaced typewriting on one side of the paper only. The title page should include the name of the author with initials or distinguishing first name only, and the name and address of the hospital or laboratory where the work was performed. The paper must include a precise summary of the work of less than 200 words. Use of abbreviation is discouraged. A separate covering letter signed by all authors must state that the data have not been published elsewhere in whole or in part and that all authors agree to publication in *Gut*. Previous publication in abstract form must be disclosed in a footnote. Papers must not be published elsewhere without prior permission of the Editorial Committee.

ACKNOWLEDGEMENT OF MANUSCRIPTS Manuscripts will only be acknowledged if an addressed postcard is enclosed.

ILLUSTRATIONS *Photographs* Unmounted photographs on glossy paper should be provided. Illustrations should not be inserted in the text but marked on the back with the figure numbers, title of paper and name of author. All photographs, graphs, diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet.

ETHICS Ethical aspects will be considered in the assessment of papers (see the Medical Research Council's publications on the ethics of human experimentation, and the World Medical Association's code of ethics, known as the Declaration of Helsinki (see *BMJ* 1964; ii: 177)).

SI UNITS All measurements except blood pressure are expressed in SI units. In tables and illustrations values are given in SI units. For general guidance on the International System of Units and some useful conversion factors, see *The SI for Health Professions* (WHO, 1977). **NB: Such conversion is the responsibility of the author.**

REFERENCES These follow the Vancouver system – that is, references numbered consecutively in the text and listed numerically with journal titles abbreviated in the style of *Index Medicus, Standard journal article.* List up to six authors, then add *et al.*

CORRECTIONS other than printers' errors may be charged to the author.

REPRINTS Reprints will be available on payment of the necessary costs; the number of reprints required should be sent to the Publishing Manager on the form provided with the proof.

NOTICE TO ADVERTISERS All applications for advertisement space and rates should be addressed to the Advertisement Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR.

NOTICE TO SUBSCRIBERS *Gut* is published monthly. The annual subscription rates are £167.00 (USA $281.00). Reduced subscriptions of £70.00 available to trainees for one year (direct only). Orders should be sent to the Subscription Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, can be sent to: *British Medical Journal*, Box 560B, Kennebunkport, Maine 04046. All enquiries, however, must be addressed to the Publisher in London.) Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. All overseas copies of the journal are sent by accelerated surface post. If required, full air mail rates and enquiries for single copies already published should be addressed to the Publisher in London.

Second class postage paid, Rahway NJ. Postmaster: send address changes to: *Gut*, c/o Mercury Airfreight International Ltd Inc, 2323 Randolph Avenue, Avenel, NJ 07001, USA. ISSN 0017–5749

Published by British Medical Association, Tavistock Square, London WC1H 9JR.
Typeset by Bedford Typesetters Ltd
Printed by Stott Brothers Ltd, Halifax